← Back to Search

Xenon-129 fMRI for Alzheimer's Disease

Q: What is the patient capacity for this research initiative?

Affirmative. Clinical trials data shows that this trial is currently recruiting participants, having been released on June 27th 2016 and most recently revised on October 25th 2022. The research requires 120 people to take part from a single location.

Q: Do I meet the criteria necessary to participate in this experiment?

Candidates for this clinical trial must be afflicted with <a href="https://www.withpower.com/clinical-trials/alzheimer&#x27;s-disease">Alzheimer's disease</a>, and between 18 to 85 years of age. An expected total of 120 participants are sought after by the research team.

Q: Is this trial open to applicants who are younger than fifty years old?

To be admitted into this medical trial, applicants must fall between 18 and 85 years of age. In comparison, there are 28 trials for minors and 551 clinical studies focused on those over the pensionable limit.

Q: Have any other trials been conducted to examine the efficacy of this remedy?

At present, 15 different clinical trials on this treatment are currently running - none of them in phase 3. The majority of these studies take place in Philadelphia, <a href="https://www.withpower.com/clinical-trials/pennsylvania">Pennsylvania</a> yet a total of 21 medical centres across the US are conducting research.

Q: Is recruitment ongoing for this investigation?

Per the information provided on clinicaltrials.gov, recruitment for this clinical trial is currently ongoing with a posting date of June 27th 2016 and an updated version published October 25th 2022.

Phase < 1

Recruiting

Led By Mitchell Albert, Ph.D.

Research Sponsored by Thunder Bay Regional Health Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Normal or corrected to normal vision

Participants meet National Institute on Aging-Alzheimer's Association for probable or possible Alzheimer's Disease dementia

Timeline

Screening 3 weeks

Treatment Varies

Follow Up three years

Awards & highlights

Study Summary

This trial aims to create a more sensitive brain imaging tool to help develop more effective drugs for Alzheimer's.

Who is the study for?

This trial is for healthy adults and those with Alzheimer's disease, aged 18-85 or 60-85 respectively. Participants must speak English, have at least 8 years of education, be able to consent and hold their breath for 20 seconds. Those with Alzheimer's need a MoCA score of at least 16 and a caregiver present during the study.Check my eligibility

What is being tested?

The study tests hyperpolarized xenon functional brain MRI against traditional proton fMRI in detecting brain function changes in Alzheimer's. It aims to improve drug development by providing more sensitive measurements of brain activity.See study design

What are the potential side effects?

There are no direct side effects mentioned from the imaging techniques used in this trial; however, participants should not be claustrophobic as they will be required to enter an MRI machine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My vision is normal or corrected to normal with glasses or contacts.

Select...

I have been diagnosed with Alzheimer's Disease.

Select...

I am between 60 and 85 years old and not breastfeeding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ three years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~three years

This trial's timeline: 3 weeks for screening, Varies for treatment, and three years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Signal-to-Noise Ratio (SNR)

Secondary outcome measures

P-Value

Trial Design

2Treatment groups

Experimental Treatment

Group I: Healthy VolunteersExperimental Treatment4 Interventions

Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.

Group II: Alzheimer's Disease ParticipantsExperimental Treatment4 Interventions

Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Xenon

Not yet FDA approved

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Thunder Bay Regional Health Research InstituteLead Sponsor

9 Previous Clinical Trials

814 Total Patients Enrolled

Thunder Bay Regional Health Sciences CentreOTHER

9 Previous Clinical Trials

3,390 Total Patients Enrolled

Thunder Bay Regional Research InstituteLead Sponsor

8 Previous Clinical Trials

714 Total Patients Enrolled

Media Library

Alzheimer's Disease Participants Clinical Trial Eligibility Overview. Trial Name: NCT02638519 — Phase < 1

Alzheimer's Disease Research Study Groups: Alzheimer's Disease Participants, Healthy Volunteers

Alzheimer's Disease Clinical Trial 2023: Alzheimer's Disease Participants Highlights & Side Effects. Trial Name: NCT02638519 — Phase < 1

Alzheimer's Disease Participants 2023 Treatment Timeline for Medical Study. Trial Name: NCT02638519 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the patient capacity for this research initiative?

"Affirmative. Clinical trials data shows that this trial is currently recruiting participants, having been released on June 27th 2016 and most recently revised on October 25th 2022. The research requires 120 people to take part from a single location."

Answered by AI

Do I meet the criteria necessary to participate in this experiment?

"Candidates for this clinical trial must be afflicted with Alzheimer's disease, and between 18 to 85 years of age. An expected total of 120 participants are sought after by the research team."

Answered by AI

Is this trial open to applicants who are younger than fifty years old?

"To be admitted into this medical trial, applicants must fall between 18 and 85 years of age. In comparison, there are 28 trials for minors and 551 clinical studies focused on those over the pensionable limit."

Answered by AI

Have any other trials been conducted to examine the efficacy of this remedy?

"At present, 15 different clinical trials on this treatment are currently running - none of them in phase 3. The majority of these studies take place in Philadelphia, Pennsylvania yet a total of 21 medical centres across the US are conducting research."

Answered by AI

Is recruitment ongoing for this investigation?

"Per the information provided on clinicaltrials.gov, recruitment for this clinical trial is currently ongoing with a posting date of June 27th 2016 and an updated version published October 25th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease

2016. "HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02638519.

All > Alzheimer Disease > Alzheimers Disease